Natus Medical Inc

Natus Medical, Inc. provides medical device solutions focuses on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Its products are used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, sleep disorders, neuromuscular diseases and balance and mobility disorders. The company was founded by Maurizio Liverani, John Robert Camber Porter, William New, Jr., Brian Prinn and William W. Moore on May 26, 1987 and is headquartered in Middleton, WI.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Natus Medical, Inc. engages in providing healthcare solutions. It also focuses on the diagnosis and treatment of central nervous and sensory system disorders. The company was founded by Maurizio Liverani, John Robert Camber Porter, William Jr. New, Brian Prinn and William W. Moore on May 26, 1987 and is headquartered in Middleton, WI.

Partnership to advance the development and distribution of innovative AutoSCORE algorithm Partnership to advance the development and distribution of innovative AutoSCORE algorithm

Natus partners with Holberg EEG to advance the diagnosis of Epilepsy

Natus Medical Incorporated (NTUS) CEO Jonathan Kennedy on Q1 2020 Results - Earnings Call Transcript

Natus Medical (NTUS) delivered earnings and revenue surprises of -81.82% and -0.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Natus Medical (NTUS) Lags Q1 Earnings and Revenue Estimates

PLEASANTON, Calif., April  06, 2020  (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced its first quarter revenue estimate and withdrew its full year 2020 guidance.

Natus Announces Preliminary First Quarter Revenue

PLEASANTON, Calif., March 20, 2020 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced the appointment of Ilan Daskal, current Chief Financial Officer & Executive Vice President of Bio-RAD Laboratories, to its board of directors and audit committee effective March 19, 2020. The Company will also nominate Mr. Daskal at its 2020 Annual Meeting of Stockholders.

Natus Medical Announces the Appointment of Ilan Daskal to the Board of Directors

Exelixis

NuVasive

The healthcare companies couldn't sidestep the COVID-19 slump.

Here's Why NuVasive, Exelixis, and Natus Medical Fell Today

Another key partner joins the Otocloud community, expanding the reach even further.

The supporting community of Otoscan® expands its global influence

Natus Medical Incorporated (NTUS) CEO Jonathan Kennedy on Q4 2019 Results - Earnings Call Transcript

Natus Medical (NTUS) delivered earnings and revenue surprises of -2.13% and 1.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Natus Medical (NTUS) Misses Q4 Earnings Estimates

PLEASANTON, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced that effective December 31, 2019 the Company has finalized and executed the previously announced transition of the Peloton hearing screening services business to Pediatrix Medical Group (“Pediatrix”).

Natus Medical Finalizes Transition of Peloton Business to Pediatrix Medical Group and Completes Signing of Strategic Agreement

PLEASANTON, Calif., Dec.  17, 2019  (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced that its Board of Directors has approved a stock repurchase program, authorizing the repurchase of up to $50 million of the Company's common stock.

Natus Announces $50 Million Share Repurchase Program

Natus Medical Incorporated (NTUS) CEO Jonathan Kennedy on Q3 2019 Results - Earnings Call Transcript

PLEASANTON, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced financial results for the three and nine months ended September 30, 2019.

Natus Medical Announces Third Quarter 2019 Financial Results

PLEASANTON, Calif., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company signed a definitive agreement to transition its Peloton hearing screening services business to Pediatrix Medical Group (“Pediatrix”). After the completion of the transition, Pediatrix will manage all newborn hearing screening services for Peloton hospitals.  As part of the transition, Natus and Pediatrix have entered into a strategic agreement where Natus will provide its best-in-class ALGO screeners and supplies to Pediatrix to support its entire hearing screening business.  Upon completion of this transition, Pediatrix will provide hearing screening services to over 500 U.S. hospitals.

Natus Medical Announces Transition of Peloton Business to Pediatrix Medical Group and Signing of Strategic Agreement

Carter's

Children's Place

Spending on baby-related products is set to increases as more millennials start a family. Capitalize on the theme by trading these stocks.

3 Stocks to Play a Millennial Parent Boom

Natus Medical Is All Grown Up

Natus Medical Incorporated (BABY) CEO Jonathan Kennedy on Q2 2019 Results - Earnings Call Transcript

Natus Medical (BABY) delivered earnings and revenue surprises of 13.33% and 2.19%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Natus Medical (BABY) Q2 Earnings and Revenues Top Estimates

Natus Medical (BABY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Natus Medical (BABY) to Report a Decline in Earnings: What to Look Out for

It's a rebuilding year for the medical device maker.

Natus Medical Continues Its Restructuring

Natus Medical's (BABY) CEO Jonathan Kennedy on Q1 2019 Results - Earnings Call Transcript

Per Natus Medical, this deal is strategically aligned with its business as besides concentrating on its core products, this sell-off will lead to planned investment in the high-growth markets.

News for Natus Medical Inc Stock (NTUS)